Dr. Edward D. Hall, a native of the Cleveland, Ohio area, received his B.S. in biology from Mount Union College in 1972 and his Ph.D. in neuropharmacology from the Cornell University Graduate School of Medical Sciences in 1976. After completing a post-doctoral fellowship at Cornell University Medical College, he joined the Northeastern Ohio Universities College of Medicine where he rose to the rank of Associate Professor of Pharmacology. In 1982, he moved to the The Upjohn Company where he initiated and lead an effort over many years to discover and develop agents for the treatment of traumatic brain and spinal cord injury and stroke. In 1997, Dr. Hall left Upjohn and joined Parke-Davis Pharmaceutical Research which is now part of Pfizer Global Research and Development (PGRD). In 2001, he was appointed Senior Director, CNS Pharmacology at PGRD-Ann Arbor. On July 1, 2002, he joined the University of Kentucky Medical Center where he is Director of the Spinal Cord and Brain Injury Research Center (SCoBIRC) and an Endowed Professor of Anatomy and Neurobiology, Neurosurgery, Neurology and Physical Medicine & Rehabilitation. Dr. Hall is an authority on the pathophysiology of acute neurological injury, particularly the role of reactive oxygen mechanisms, and the design and development of antioxidant neuroprotective drugs. He played a leading role in the discovery and development of high dose methylprednisolone therapy for acute spinal cord injury. For this work, he received the Upjohn Achievement in Science and Medicine Award in 1991. In 2008, he was elected to the National Spinal Cord Injury Association SCI Hall of Fame. In addition, Dr. Hall was co-discoverer of the 21-aminosteroids (“lazaroids”) including tirilazad mesylate which was the subject of phase III clinical trials in moderate and severe TBI and in SCI and was approved for the treatment of aneurysmal subarachnoid hemorrhage in several European and Australasian countries. His ongoing research at the University of Kentucky which is directed at the discovery of novel neuroprotective pharmacological strategies for acute TBI and SCI is funded by the National Institute of Neurological Disorders and Stroke and the Kentucky Spinal Cord & Head Injury Research Trust. Dr. Hall is currently a Section Editor for the Journal of Neurotrauma as well as serving, or having served, on the editorial boards of the Journal of Cerebral Blood Flow & Metabolism, Restorative Neurology and Neuroscience and Biochemical Pharmacology. In addition, he has served as a chair, a regular member or an ad hoc reviewer for several National Institute for Neurological Disorders and Stroke (NINDS) study sections, as Chair of the Veterans Administration Neurobiology C Merit Review Panel and as a member of the Paralyzed Veterans of America Spinal Cord Research Foundation Scientific Advisory Board. He also served as President of the National Neurotrauma Society from 2007-2008. In 2007, he founded Stallion Therapeutics, Inc. which is focused on the discovery and early development of neuroprotective pharmacological agents for acute CNS injury and other neurocritical care indications.

Research interest of Edward D. Hall includes Neuropharmacology.